Rubius Therapeutics Inc. Common Stock
(NASDAQ:RUBY)
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
RUBY Overview
None
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$0.7017 |
Previous Close Volume |
140300 |